Varicose Veins Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Type (Endovenous Ablation, Sclerotherapy, Surgical Ligation & Stripping), By Component (Ablation Devices, Radiofrequency Ablation Devices, Laser Ablation Devices, Venous Closure Products, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Overview

Global Varicose Veins Treatment Market was valued at USD 1.45 billion in 2024 and is expected to reach USD 2.08 billion by 2030 with a CAGR of 6.32% during the forecast period. The global varicose veins treatment market is experiencing significant growth due to increasing awareness of venous disorders and the rising demand for minimally invasive procedures.

For instance, according to the study from Germany’s Institute of Quality and Efficiency in Healthcare estimates that roughly 20% of adults will experience varicose veins at some point in their lives. Although spider veins are more prevalent among the elderly, younger people can also be affected by these venous conditions. Varicose veins, which occur when veins become enlarged and twisted due to faulty valves, are becoming more prevalent, especially among aging populations and individuals with sedentary lifestyles. With more patients seeking medical attention for both cosmetic and health reasons, healthcare providers are expanding their offerings for effective treatment options. Technological advancements in laser therapy, radiofrequency ablation, and sclerotherapy are transforming the treatment landscape, offering quicker recovery times, reduced pain, and minimal scarring. These innovations have made outpatient procedures more accessible and appealing to patients, boosting market adoption.

Key Market Drivers

Rising Prevalence of Varicose Veins and Venous Disorders

The rising prevalence of varicose veins and venous disorders is a major factor driving the growth of the global varicose veins treatment market. Varicose veins are a common condition characterized by swollen, twisted veins that most often occur in the legs due to weak or damaged vein walls and valves. Several contributing factors have led to an increase in cases worldwide. Aging is a primary risk factor, as vein elasticity naturally declines over time, making older adults more susceptible. Hormonal changes, particularly during pregnancy and menopause, also contribute to the weakening of vein walls, increasing the likelihood of varicose vein development, especially among women. Obesity and a sedentary lifestyle are closely linked to venous insufficiency. Excess body weight places additional pressure on leg veins, while prolonged sitting or standing impairs circulation and contributes to valve dysfunction. These lifestyle patterns are increasingly common across both developed and developing nations, resulting in a higher burden of venous disorders. Occupational risk is another concern, with many individuals in professions requiring long hours of standing or sitting—such as healthcare workers, teachers, and office employees—experiencing higher susceptibility.

As awareness of varicose veins has grown, more individuals are seeking medical care not only for physical symptoms such as pain, swelling, and heaviness in the legs but also for cosmetic concerns. Patients are becoming more proactive about managing early signs of venous disorders to prevent complications like chronic venous insufficiency, ulcers, and deep vein thrombosis. This rising demand for diagnosis and intervention is pushing healthcare systems and providers to invest in advanced treatment options. The increasing prevalence across diverse population segments continues to generate significant momentum for innovation and expansion within the varicose veins treatment market, as the need for effective, accessible, and minimally invasive solutions becomes more urgent.

Growing Preference for Minimally Invasive Procedures

The growing preference for minimally invasive procedures is significantly shaping the global varicose veins treatment market. For instance, in May 2022, THERACLION launched SONOVEIN HD, a scalable robotic platform for non-invasive echotherapy. This innovative system combines advanced imaging technology from SuperSonic Imagine with the only extracorporeal therapeutic ultrasound solution, offering patients a safer, less invasive alternative to traditional treatments. Such breakthroughs highlight the market’s shift toward effective, patient-friendly procedures, fueling demand and expanding treatment options worldwide. Patients today are increasingly opting for treatment methods that offer faster recovery, minimal pain, and reduced risk of complications compared to traditional surgical interventions. Conventional vein stripping surgeries, once the primary method for treating varicose veins, are being replaced by advanced techniques such as endovenous laser treatment (EVLT), radiofrequency ablation (RFA), and foam sclerotherapy. These procedures are often performed in outpatient settings and require only local anesthesia, making them more convenient and less intimidating for patients. Minimally invasive approaches offer several clinical advantages. They involve smaller incisions or needle-based access, which leads to minimal scarring and significantly lower chances of infection. Recovery time is much shorter, enabling patients to return to normal activities within a few days. As a result, healthcare providers are witnessing a rise in patient volumes seeking these treatments, especially among working individuals and older adults who prioritize faster healing and improved quality of life.

The appeal of these procedures is further enhanced by the use of ultrasound and imaging technologies that ensure higher precision and success rates. Patients report better cosmetic outcomes and long-term results with fewer side effects, increasing overall satisfaction. The reduced need for hospitalization and post-operative care also contributes to cost-effectiveness, making these treatments attractive to both patients and healthcare systems. With rising awareness of these benefits, clinics and hospitals are investing in the necessary equipment and training to offer advanced vein care solutions. The trend toward less invasive treatment is not only meeting patient expectations but also creating new growth opportunities for medical device manufacturers and service providers within the varicose veins treatment market. As this shift continues, minimally invasive procedures are expected to remain a dominant force in driving market expansion.

Rising Awareness and Early Diagnosis

Rising awareness and early diagnosis are playing a crucial role in the growth of the global varicose veins treatment market. For instance, in April 2022, Italian medical device company I-VASC secured EUR 1.8 million in Series A funding to launch its VELEX device. Approved with CE Mark in May 2021, VELEX treats chronic venous insufficiency and varicose veins using the innovative Empty Vein Ablation (EVA) procedure, offering an effective option that encourages earlier intervention and improved patient outcomes. As public understanding of venous disorders improves, more individuals are recognizing the signs and symptoms of varicose veins, prompting them to seek medical advice at an earlier stage. This shift toward proactive health management is a result of growing health literacy, targeted awareness campaigns by healthcare organizations, and increased visibility of venous conditions in both digital and traditional media. Individuals are now more informed about the risks associated with untreated varicose veins, such as skin ulcers, bleeding, and chronic venous insufficiency, which encourages timely diagnosis and intervention. Primary care providers and specialists are also placing greater emphasis on screening for venous disorders, particularly among at-risk populations such as the elderly, pregnant women, and people with sedentary lifestyles or a family history of vein disease. Improved diagnostic tools, including Doppler ultrasound and duplex scanning, allow for non-invasive, accurate assessments of venous function, which supports early treatment planning and better patient outcomes.

Early diagnosis not only reduces the risk of complications but also increases the effectiveness of minimally invasive treatments. When addressed in the initial stages, varicose veins can often be managed with less complex procedures, improving recovery time and reducing healthcare costs. The shift in patient behavior toward seeking treatment for both health and cosmetic reasons has led to increased footfall in vein clinics and vascular centers. Healthcare systems are responding by integrating venous care into routine check-ups and expanding access to specialized services. The focus on early detection is contributing to a broader treatment base, accelerating market demand for advanced technologies and therapies. Rising awareness combined with timely diagnosis is expected to remain a strong driver in shaping the future of varicose veins treatment worldwide.

Download Free Sample Report

Key Market Challenges

High Treatment Costs

High treatment costs remain one of the major challenges impacting the global varicose veins treatment market. Although minimally invasive procedures have transformed care by offering better outcomes and faster recovery, they often come at a premium. Techniques such as endovenous laser treatment (EVLT), radiofrequency ablation (RFA), and ultrasound-guided foam sclerotherapy require advanced medical equipment, skilled professionals, and precise imaging systems. These elements drive up the overall cost of diagnosis and treatment, making it less accessible for a large segment of the population, especially in low- and middle-income countries. The financial burden is compounded by the fact that varicose vein treatments are frequently categorized as elective or cosmetic in nature, which limits insurance coverage or reimbursement eligibility. Many insurance providers do not cover these procedures unless there is documented evidence of medical necessity, such as chronic pain, ulceration, or venous insufficiency. As a result, out-of-pocket expenses can be substantial, deterring patients from seeking timely care.

In public healthcare systems, cost constraints can lead to long wait times and limited access to specialized care, particularly when prioritization is given to life-threatening conditions. Private healthcare facilities, while offering advanced treatments with minimal delays, often remain financially out of reach for a large portion of the population. This cost-related disparity results in delayed intervention, increased complication rates, and higher long-term healthcare expenses. Healthcare providers and manufacturers are working to address this challenge by introducing cost-effective technologies and expanding the use of outpatient treatment settings, which can help reduce hospital overhead. However, until there is broader access to affordable treatment and improved insurance support, high costs will continue to be a barrier for many patients. This challenge underscores the need for strategic pricing, wider public healthcare funding, and awareness around the long-term benefits of early varicose vein treatment.

Limited Insurance Coverage and Reimbursement

Limited insurance coverage and reimbursement present a significant challenge in the global varicose veins treatment market. Many healthcare payers classify varicose vein procedures as cosmetic rather than medically necessary, especially in the early stages of the condition. As a result, insurance providers often deny claims or provide only partial reimbursement unless patients can demonstrate severe symptoms such as chronic leg pain, swelling, ulceration, or venous insufficiency confirmed through diagnostic imaging. This requirement for clinical justification delays access to treatment and discourages patients from seeking early medical intervention. Patients who do not meet stringent criteria for coverage are forced to bear the full cost of treatment out-of-pocket. Given the high costs associated with procedures like endovenous laser treatment (EVLT), radiofrequency ablation (RFA), and sclerotherapy, many individuals opt to delay or forgo treatment entirely. This contributes to disease progression, increases the risk of complications, and raises long-term healthcare costs. The lack of standardized insurance policies across different regions and providers adds to the confusion and limits access to timely care.

In countries with public healthcare systems, reimbursement policies may be more structured but still limited by budget constraints. Treatments may be restricted to more severe cases, resulting in long waiting periods for approval or access. This delayed care can negatively affect outcomes and patient satisfaction. The inconsistency in insurance support also impacts healthcare providers and clinics, who may struggle with administrative burdens and delayed payments. Manufacturers of treatment devices face challenges in achieving broader adoption of their technologies due to the limited financial support available to end users. To overcome this barrier, clearer clinical guidelines and more inclusive insurance policies are needed. Aligning coverage with evidence-based outcomes could ensure that patients receive necessary treatments earlier and reduce the burden on healthcare systems over time.

Key Market Trends

Rapid Adoption of Endovenous Laser Ablation (EVLA)

The rapid adoption of endovenous laser ablation (EVLA) is significantly transforming the global varicose veins treatment market. EVLA has emerged as a preferred treatment method for varicose veins due to its minimally invasive nature, high success rate, and faster recovery compared to traditional surgical procedures like vein stripping. Patients and physicians alike are drawn to its clinical advantages, including reduced postoperative pain, minimal scarring, and a low risk of complications. These benefits align well with the growing demand for outpatient procedures that offer convenience without compromising effectiveness. EVLA uses targeted laser energy to seal faulty veins, causing them to collapse and eventually be absorbed by the body. The procedure is typically performed under local anesthesia, allowing patients to return to daily activities within a short period. This efficiency has made EVLA a go-to option for individuals seeking both functional and cosmetic relief from varicose veins. As awareness spreads about its effectiveness and safety profile, healthcare providers are increasingly incorporating EVLA into their service offerings. The availability of advanced laser systems with improved wavelength control, cooling technologies, and fiber-optic precision is further accelerating the use of EVLA in clinical practice. Medical device companies are actively investing in research and development to enhance system performance and user experience, ensuring better patient outcomes and procedure efficiency. Clinics and hospitals are adopting these technologies to stay competitive and meet patient expectations for modern, less invasive solutions. With insurance providers beginning to recognize the long-term cost savings of minimally invasive treatments like EVLA, reimbursement support is also gradually improving in some regions. This shift is helping to make the procedure more accessible. As the market continues to favor less invasive approaches, the role of EVLA is expected to grow, solidifying its place as a key driver of innovation and expansion in varicose vein management.

Sclerotherapy Leading Amid Device Innovation

Sclerotherapy continues to hold a leading position in the global varicose veins treatment market, driven by ongoing device innovation and its proven effectiveness. This treatment involves injecting a sclerosant solution directly into the affected veins, causing them to collapse and eventually be reabsorbed by the body. Its minimally invasive nature, combined with the ability to treat both small spider veins and larger varicose veins, makes it a versatile and widely accepted option among physicians and patients alike. The relatively low cost, minimal discomfort, and quick recovery associated with sclerotherapy contribute to its sustained popularity. Recent advancements in sclerotherapy devices have enhanced the precision and safety of the procedure. Automated foam sclerotherapy systems, which create a more stable foam form of the sclerosant, improve vein contact time and treatment efficacy. Devices like the Varixio Pod Air and similar foam delivery systems are designed to increase the consistency and accuracy of injections, reducing the risk of side effects such as bruising or skin discoloration. These innovations are making sclerotherapy more reliable and easier to perform in outpatient settings, boosting its adoption.

Clinicians benefit from the improved control and visibility these new devices offer, allowing for better treatment planning and patient outcomes. The rise of ultrasound-guided sclerotherapy techniques has also contributed to its growth by enabling targeted treatment of deeper veins that were once difficult to manage non-surgically. As patient demand for minimally invasive and cosmetically appealing options grows, sclerotherapy remains a mainstay, supported by ongoing technological progress.  The integration of innovative delivery devices and improved formulations of sclerosants strengthens sclerotherapy’s role in varicose vein management. This combination is expanding treatment options, making sclerotherapy a key market driver. It continues to attract a broad patient base, from those seeking aesthetic improvements to individuals with more advanced venous disease, solidifying its leading status amid evolving varicose vein therapies.

Segmental Insights

Component Insights

Based on component, Laser Ablation Devices was dominated position in the global market. Laser Ablation has gained widespread acceptance due to its precision, effectiveness, and minimally invasive approach. It uses targeted laser energy to close off faulty veins, offering high success rates with reduced pain and faster recovery compared to traditional surgical methods. Patients benefit from minimal scarring and quicker return to daily activities, making it a preferred choice. Radiofrequency Ablation Devices are also significant but tend to trail slightly behind laser devices in terms of market share. They offer similar benefits, using radiofrequency energy to achieve vein closure, but laser systems have generally been more widely adopted due to earlier technological development and broader clinical acceptance. Venous Closure Products, such as adhesives and clips, represent an emerging category but have not yet reached the market penetration levels of laser or radiofrequency devices. These products offer alternative methods for vein closure but remain limited to specific clinical situations. Other device categories, including foam sclerotherapy delivery systems, complement ablation devices but are not direct competitors in the same segment. The extensive clinical evidence supporting laser ablation, combined with continuous technological improvements and growing patient preference for minimally invasive treatments, underpins the dominance of Laser Ablation Devices in the varicose veins treatment market.

Download Free Sample Report

Regional Insights

North America dominated the global varicose veins treatment market due to several interrelated factors. The region benefits from a well-established healthcare infrastructure with widespread access to advanced medical technologies and highly skilled healthcare professionals specializing in vascular treatments. High awareness levels among patients and physicians about varicose vein complications and the availability of effective minimally invasive treatment options drive demand. The presence of major medical device manufacturers and continuous innovation in treatment technologies, such as endovenous laser ablation and radiofrequency ablation, contributes to market growth. These innovations are rapidly adopted in North America, supported by strong research and development activities and favorable regulatory environments that expedite product approvals. Reimbursement policies and insurance coverage in North America are more supportive of advanced varicose vein treatments compared to other regions. Many insurance providers recognize the medical necessity of minimally invasive procedures, making these treatments financially accessible to a larger patient base. The region’s aging population also contributes to increasing prevalence rates of venous disorders, fueling demand for treatment. Patient preference for outpatient procedures and cosmetically appealing solutions aligns well with the minimally invasive techniques commonly used in North America. The combination of advanced healthcare infrastructure, supportive reimbursement, technological leadership, and rising patient awareness ensures North America maintains its dominant position in the global varicose veins treatment market.

Recent Developments

• In November 2024, a long-term randomized trial revealed that endothermal ablation significantly outperforms surgery in treating varicose veins. The study showed that patients receiving endothermal ablation experienced better outcomes, including lower recurrence rates and faster recovery times, compared to those who underwent traditional surgical methods. This minimally invasive procedure uses heat to close faulty veins, offering less pain and scarring. The trial’s results reinforce the growing preference for endothermal ablation as the standard treatment, highlighting its effectiveness and benefits over surgery in managing varicose veins long term.
• In May 2024, Sanford successfully helped a patient clear varicose vein using three different treatment methods. By combining minimally invasive techniques tailored to the patient’s condition, they achieved effective vein closure and improved circulation. This multi-approach strategy highlights Sanford’s commitment to personalized care, offering patients comprehensive solutions for varicose vein treatment that reduce symptoms and enhance recovery.
• In March 2023, Englewood Health completed an FDA-approved clinical trial for Sonovein echotherapy, a noninvasive ultrasound treatment for varicose veins. The single-center, investigator-initiated study demonstrated a 95% success rate, showcasing Sonovein as a promising new option for varicose vein therapy. This breakthrough highlights the potential of therapeutic ultrasound in providing effective, minimally invasive care for patients with venous disorders.

Key Market Players

• Alma Lasers Limited
• Medtronic Plc.
• Boston Scientific Corporation (Lumenis Corporation)
• Sciton, Inc
• Merit Medical Systems, Inc.
• BTG International Limited
• Energist Limited
• Teleflex Incorporated
• AngioDynamics, Inc.
• El. En SpA Group (Quanta System)

Report Scope:

In this report, the Global Varicose Veins Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Varicose Veins Treatment Market, By Type:

o   Endovenous Ablation

o   Sclerotherapy

o   Surgical Ligation & Stripping  

• Varicose Veins Treatment Market, By Component:

o   Ablation Devices

o   Radiofrequency Ablation Devices

o   Laser Ablation Devices

o   Venous Closure Products

o   Others

• Varicose Veins Treatment Market, By End User:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Varicose Veins Treatment Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Varicose Veins Treatment Market.

Available Customizations:

Global Varicose Veins Treatment Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional Market players (up to five).